# A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors

> **NCT00404508** · PHASE2 · COMPLETED · sponsor: **National Institute of Cancerología** · enrollment: 15 (—)

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** Hydralazine and magnesium valproate

## Key facts

- **NCT ID:** NCT00404508
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 15 (—)
- **Last updated:** 2006-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404508, "A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00404508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*